

Fully Funded Clinical Trial for Dogs with Metastatic Osteosarcoma

Dogs who have undergone amputation and follow up carboplatin chemotherapy and have developed measurable metastatic disease are eligible

This trial will evaluate genetically engineered off-the-shelf immune cells known as invariant NKT cells that aim to identify and kill target cancer cells.

Patients will need to travel to the University of Pennsylvania for all trial visits.



Contact Dr. Nicola Mason
BVetMed, PhD, DACVIM, FRCVS
for more information



nmason@vet.upenn.edu



(215) 898-3996